Pleural mesothelioma is a rare and aggressive form of cancer in which evaluating treatment response has traditionally been complex and prone to error. The existing international standard, RECIST, falls short in terms of accuracy according to the researchers involved. The new AI model from the NKI changes this in a fundamental way, offering patients greater certainty about their treatment outcomes and enabling more tailored approaches to care.

Beyond the direct clinical benefits for patients, the model also carries significance for medical research. By making tumor assessment in clinical trials more reliable and efficient, it has the potential to accelerate the development of new treatments. More accurate measurement methods in trials produce better data, which in turn supports faster and more well-founded conclusions about the effectiveness of new therapies.

The model was developed by physicians and researchers at the NKI and represents a concrete application of artificial intelligence in oncological practice. The results demonstrate that AI can surpass human assessors in specific diagnostic tasks, opening new perspectives for the integration of AI tools in cancer care and clinical research.